KemPharm, Inc.

Canaccord Genuity Acted as Exclusive Financial Advisor to KemPharm, Inc. on Its Acquisition of Substantially All Assets and Operations from Orphazyme A/S

KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, has acquired arimoclomol, an orally-delivered, first-in-class heat shock protein (HSP) amplifier being developed as a treatment for Niemann-Pick disease type C (NPC), from Orphazyme A/S (ORPHA.CO: ORPH) (Orphazyme). Under the terms of the agreement, KemPharm purchased all assets and operations of Orphazyme related to arimoclomol and will settle all actual outstanding liabilities to creditors with a single cash payment of $12.8 million (USD). In addition, KemPharm has agreed to assume the estimated reserve liabilities of $5.2 million (USD) related to revenue in 2021 and 2022 generated from the EAP for arimoclomol in France. Orphazyme completed the sale to KemPharm on May 31, 2022. Canaccord Genuity acted as exclusive financial advisor to KemPharm, Inc.​​​​​​​  

KemPharm is a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases through its proprietary LAT® (Ligand Activated Therapy) platform technology. KemPharm utilizes its proprietary LAT® platform technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm’s prodrug product candidate pipeline is focused on the high need areas of idiopathic hypersomnia (IH) and other CNS/rare diseases. In addition, the U.S. Food and Drug Administration (FDA) has approved AZSTARYS®, a new once-daily treatment for ADHD in patients aged six years and older containing KemPharm’s prodrug, serdexmethylphenidate (SDX), which is being commercialized by Corium, Inc. in the U.S., and APADAZ®, an immediate-release combination product containing benzhydrocodone, KemPharm’s prodrug of hydrocodone, and acetaminophen, which is being commercialized by KVK-Tech, Inc. in the U.S. ​​​​​​​  

The Canaccord Genuity team consisted of Eugene Rozelman, Esther Lee, and Sean Pritchett.